Polatuzumab Vedotin As a Salvage Treatment in Relapsed or Refractory DLBCL: Single Center Experience

被引：0
|
作者：
Bin Morya, Marwa [1 ]
Marei, Mohammed A. [2 ]
Tailor, Imran K. [2 ]
Alrajhi, Abdullah M. [3 ]
Alnakhli, Adel [4 ]
Alnajjar, Foud [5 ]
Alnoamani, Mohammed S. [2 ]
Alshehri, Hassan [2 ]
Motabi, Ibraheem H. [2 ]
AlShehry, Nawal [2 ]
Alfayez, Mansour [2 ]
机构：
[1] King Fahad Med City, Hematol Dept, Riyadh, Saudi Arabia
[2] King Fahad Med City, Dept Adult Hematol BMT, Comprehens Canc Ctr, Riyadh, Saudi Arabia
[3] King Fahad Med City, Hematol, Riyadth, Saudi Arabia
[4] King Fahad Med City, Clin Pharm Dept, Riyadh, Saudi Arabia
[5] King Fahad Med City, Riyadh, Saudi Arabia
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-150242
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4558
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
    Liebers, Nora
    Duell, Johannes
    Fitzgerald, Donnacha
    Kerkhoff, Andrea
    Noerenberg, Daniel
    Kaebisch, Eva
    Acker, Fabian
    Fuhrmann, Stephan
    Leng, Corinna
    Welslau, Manfred
    Chemnitz, Jens
    Middeke, Jan-Moritz
    Weber, Thomas
    Holtick, Udo
    Trappe, Ralf
    Pfannes, Roald
    Liersch, Ruediger
    Spoer, Christian
    Fuxius, Stefan
    Gebauer, Niklas
    Caille, Leandra
    Geer, Thomas
    Koenecke, Christian
    Keller, Ulrich
    Claus, Rainer
    Mougiakakos, Dimitrios
    Mayer, Stephanie
    Huettmann, Andreas
    Pott, Christiane
    Trummer, Arne
    Wulf, Gerald
    Brunnberg, Uta
    Bullinger, Lars
    Hess, Georg
    Mueller-Tidow, Carsten
    Glass, Bertram
    Lenz, Georg
    Dreger, Peter
    Dietrich, Sascha
    BLOOD ADVANCES, 2021, 5 (13) : 2707 - 2716
  • [2] Randomized Phase 2 Trial of Polatuzumab Vedotin With Bendamustine and Rituximab in Relapsed/Refractory FL and DLBCL
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (08) : 14 - 16
  • [3] BRENTUXIMAB VEDOTIN FOR RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: SINGLE CENTER EXPERIENCE
    Valiev, Timur
    Tsaplina, Nataly
    Kirgizov, Kirill
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S589 - S589
  • [4] SALVAGE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA WITH BRENTUXIMAB VEDOTIN: THE GREEK EXPERIENCE
    Tsirigotis, P.
    Vassilakopoulos, T.
    Bousiou, Z.
    Mpatsis, I.
    Gkirkas, K.
    Sakellari, I.
    Papageorgiou, S.
    Roussou, P.
    Pangalis, G.
    Galani, Z.
    Moschoyianni, M.
    Vassilopoulos, G.
    Repoussis, P.
    Megalakaki, E.
    Michalis, E.
    Anagnostopoulos, N.
    Calpadaki, C.
    Papadaki, H.
    Margaritis, D.
    Chatzimichail, E.
    Briassoulis, E.
    Spyridonidis, A.
    Grentzelias, D.
    Anargyrou, K.
    Tsionos, K.
    Mpanti, A.
    Poulakidas, E.
    Palaska, C.
    Gribabi, D.
    Apostolidis, J.
    Pappa, V.
    Harhalakis, N.
    Panayiotidis, P.
    Konstantopoulos, K.
    Anagnostopoulos, A.
    Angelopoulou, M.
    HAEMATOLOGICA, 2015, 100 : 454 - 455
  • [5] Ibrutinib as a monotherapy for relapsed or refractory DLBCL patients: a single-center experience
    Ekinci, O.
    Merter, M.
    LEUKEMIA RESEARCH, 2019, 85 : S55 - S55
  • [6] Polatuzumab vedotin plus bendamustine and rituximab in relapsed/ refractory DLBCL: survival update and new extension cohort data
    Sehn, Laurie H.
    Hertzberg, Mark
    Opat, Stephen
    Herrera, Alex F.
    Assouline, Sarit
    Flowers, Christopher R.
    Kim, Tae Min
    McMillan, Andrew
    Ozcan, Muhit
    Safar, Violaine
    Salles, Gilles
    Ku, Grace
    Hirata, Jamie
    Chang, Yi Meng
    Musick, Lisa
    Matasar, Matthew J.
    BLOOD ADVANCES, 2022, 6 (02) : 533 - 543
  • [7] Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
    Northend, Michael
    Wilson, William
    Osborne, Wendy
    Fox, Christopher P.
    Davies, Andrew J.
    El-Sharkawi, Dima
    Phillips, Elizabeth H.
    Sim, Hau Wui
    Sadullah, Shalal
    Shah, Nimish
    Peng, Ying Ying
    Qureshi, Iman
    Addada, Juanah
    Mora, Rocio Figueroa
    Phillips, Neil
    Kuhnl, Andrea
    Davies, Elizabeth
    Wrench, David
    McKay, Pamela
    Karpha, Indrani
    Cowley, Anna
    Karim, Richard
    Challenor, Sarah
    Singh, Vikram
    Burton, Cathy
    Auer, Rebecca
    Williams, Chris
    Cunningham, Joel
    Broom, Angus
    Arasaretnam, Anita
    Roddie, Claire
    Menne, Tobias
    Townsend, William
    BLOOD ADVANCES, 2022, 6 (09) : 2920 - 2926
  • [8] Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study
    Fujino, Takahiro
    Okamoto, Haruya
    Nishiyama, Daichi
    Hayata, Hiroki
    Sasaki, Nana
    Kobayashi, Tsutomu
    Maekura, Chika
    Kuwahara-Ota, Saeko
    Takimoto-Shimomura, Tomoko
    Shimura, Kazuho
    Kawaji-Kanayama, Yuka
    Inoue, Yu
    Chinen, Shotaro
    Isa, Reiko
    Tsukamoto, Taku
    Mizutani, Shinsuke
    Shimura, Yuji
    Kaneko, Hiroto
    Nakao, Mitsushige
    Fuchida, Shinichi
    Takahashi, Ryoichi
    Uchiyama, Hitoji
    Uoshima, Nobuhiko
    Kuroda, Junya
    Kyoto Clin Hematol Study Grp
    LEUKEMIA & LYMPHOMA, 2025,
  • [9] Polatuzumab Vedotin As an Effective Salvage Therapy for Relapsed/Refractory Mantle Cell Lymphoma Resistantance to BTK and BCL Inhibitors
    Yang, Ping
    Li, Chunyuan
    Yang, Yuan
    Liu, Shuozi
    Wang, Jing
    Chen, Yingtong
    Zhang, Weilong
    Jing, Hongmei
    BLOOD, 2024, 144 : 6303 - 6303
  • [10] Definitive salvage chemotherapy for the treatment of refractory/relapsed non-Hodgkin lymphoma, a single center experience
    Hafez, Rania
    Hussein, Safinaz
    Ismail, Marwa
    ALEXANDRIA JOURNAL OF MEDICINE, 2018, 54 (04) : 679 - 683
12345